Cargando…
The effects of nebulized ketamine and intravenous magnesium sulfate on corticosteroid resistant asthma exacerbation; a randomized clinical trial
BACKGROUND AND AIMS: Asthma exacerbation is defined as an acute attack of shortness of breath with more than 25% decrease in morning peak flow compared to the baseline on 2 consecutive days, which requires immediate standard therapy. The majority of asthmatic patients are considered to be steroid-se...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8630847/ https://www.ncbi.nlm.nih.gov/pubmed/34847965 http://dx.doi.org/10.1186/s40733-021-00081-1 |
_version_ | 1784607441591205888 |
---|---|
author | Farshadfar, Kimia Sohooli, Maryam Shekouhi, Ramin Taherinya, Ali Qorbani, Mostafa Rezaei-kojani, Mehdi |
author_facet | Farshadfar, Kimia Sohooli, Maryam Shekouhi, Ramin Taherinya, Ali Qorbani, Mostafa Rezaei-kojani, Mehdi |
author_sort | Farshadfar, Kimia |
collection | PubMed |
description | BACKGROUND AND AIMS: Asthma exacerbation is defined as an acute attack of shortness of breath with more than 25% decrease in morning peak flow compared to the baseline on 2 consecutive days, which requires immediate standard therapy. The majority of asthmatic patients are considered to be steroid-sensitive; however, corticosteroid-resistant asthma is a subset of asthma with poor response to corticosteroids and is responsible for frequent hospital admissions. In this study we aimed to compare the effects of two enhancing strategies, the nebulized ketamine and IV magnesium sulfate, in treatment of severe steroid resistant asthma. MATERIALS AND METHODS: This double-blind randomized clinical trial was conducted on patients who presented to a referral clinic in Alborz, Iran. Using random allocation, patients were divided into two groups. The first group was treated with nebulized ketamine and the second group was treated with intravenous magnesium sulfate. Peak expiratory flow rates were assessed before the intervention, 30 and 60 min after the intervention and compared with the aid of SPSS software. RESULTS: The Peak expiratory flow rates before the intervention, 30 min and 60 min after the intervention was statistically significantly different in both ketamine and magnesium sulfate groups. Peak expiratory flow rates change between 0 and 60 min were 29.4 and 15.2% in the ketamine and magnesium sulfate group respectively. Although the ketamine group showed much higher increase in mean PEFR compared to the MgSO(4) groups, there was no statistically significant difference across both groups. CONCLUSION: Our study concluded that combined with standard therapy, both ketamine and IV magnesium sulfate are effective agents in the improvement of PEFR in patients with acute severe asthma that failed to respond to traditional therapies. However, there were no statistically significant difference between the two groups. |
format | Online Article Text |
id | pubmed-8630847 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-86308472021-12-01 The effects of nebulized ketamine and intravenous magnesium sulfate on corticosteroid resistant asthma exacerbation; a randomized clinical trial Farshadfar, Kimia Sohooli, Maryam Shekouhi, Ramin Taherinya, Ali Qorbani, Mostafa Rezaei-kojani, Mehdi Asthma Res Pract Research BACKGROUND AND AIMS: Asthma exacerbation is defined as an acute attack of shortness of breath with more than 25% decrease in morning peak flow compared to the baseline on 2 consecutive days, which requires immediate standard therapy. The majority of asthmatic patients are considered to be steroid-sensitive; however, corticosteroid-resistant asthma is a subset of asthma with poor response to corticosteroids and is responsible for frequent hospital admissions. In this study we aimed to compare the effects of two enhancing strategies, the nebulized ketamine and IV magnesium sulfate, in treatment of severe steroid resistant asthma. MATERIALS AND METHODS: This double-blind randomized clinical trial was conducted on patients who presented to a referral clinic in Alborz, Iran. Using random allocation, patients were divided into two groups. The first group was treated with nebulized ketamine and the second group was treated with intravenous magnesium sulfate. Peak expiratory flow rates were assessed before the intervention, 30 and 60 min after the intervention and compared with the aid of SPSS software. RESULTS: The Peak expiratory flow rates before the intervention, 30 min and 60 min after the intervention was statistically significantly different in both ketamine and magnesium sulfate groups. Peak expiratory flow rates change between 0 and 60 min were 29.4 and 15.2% in the ketamine and magnesium sulfate group respectively. Although the ketamine group showed much higher increase in mean PEFR compared to the MgSO(4) groups, there was no statistically significant difference across both groups. CONCLUSION: Our study concluded that combined with standard therapy, both ketamine and IV magnesium sulfate are effective agents in the improvement of PEFR in patients with acute severe asthma that failed to respond to traditional therapies. However, there were no statistically significant difference between the two groups. BioMed Central 2021-11-30 /pmc/articles/PMC8630847/ /pubmed/34847965 http://dx.doi.org/10.1186/s40733-021-00081-1 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Research Farshadfar, Kimia Sohooli, Maryam Shekouhi, Ramin Taherinya, Ali Qorbani, Mostafa Rezaei-kojani, Mehdi The effects of nebulized ketamine and intravenous magnesium sulfate on corticosteroid resistant asthma exacerbation; a randomized clinical trial |
title | The effects of nebulized ketamine and intravenous magnesium sulfate on corticosteroid resistant asthma exacerbation; a randomized clinical trial |
title_full | The effects of nebulized ketamine and intravenous magnesium sulfate on corticosteroid resistant asthma exacerbation; a randomized clinical trial |
title_fullStr | The effects of nebulized ketamine and intravenous magnesium sulfate on corticosteroid resistant asthma exacerbation; a randomized clinical trial |
title_full_unstemmed | The effects of nebulized ketamine and intravenous magnesium sulfate on corticosteroid resistant asthma exacerbation; a randomized clinical trial |
title_short | The effects of nebulized ketamine and intravenous magnesium sulfate on corticosteroid resistant asthma exacerbation; a randomized clinical trial |
title_sort | effects of nebulized ketamine and intravenous magnesium sulfate on corticosteroid resistant asthma exacerbation; a randomized clinical trial |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8630847/ https://www.ncbi.nlm.nih.gov/pubmed/34847965 http://dx.doi.org/10.1186/s40733-021-00081-1 |
work_keys_str_mv | AT farshadfarkimia theeffectsofnebulizedketamineandintravenousmagnesiumsulfateoncorticosteroidresistantasthmaexacerbationarandomizedclinicaltrial AT sohoolimaryam theeffectsofnebulizedketamineandintravenousmagnesiumsulfateoncorticosteroidresistantasthmaexacerbationarandomizedclinicaltrial AT shekouhiramin theeffectsofnebulizedketamineandintravenousmagnesiumsulfateoncorticosteroidresistantasthmaexacerbationarandomizedclinicaltrial AT taherinyaali theeffectsofnebulizedketamineandintravenousmagnesiumsulfateoncorticosteroidresistantasthmaexacerbationarandomizedclinicaltrial AT qorbanimostafa theeffectsofnebulizedketamineandintravenousmagnesiumsulfateoncorticosteroidresistantasthmaexacerbationarandomizedclinicaltrial AT rezaeikojanimehdi theeffectsofnebulizedketamineandintravenousmagnesiumsulfateoncorticosteroidresistantasthmaexacerbationarandomizedclinicaltrial AT farshadfarkimia effectsofnebulizedketamineandintravenousmagnesiumsulfateoncorticosteroidresistantasthmaexacerbationarandomizedclinicaltrial AT sohoolimaryam effectsofnebulizedketamineandintravenousmagnesiumsulfateoncorticosteroidresistantasthmaexacerbationarandomizedclinicaltrial AT shekouhiramin effectsofnebulizedketamineandintravenousmagnesiumsulfateoncorticosteroidresistantasthmaexacerbationarandomizedclinicaltrial AT taherinyaali effectsofnebulizedketamineandintravenousmagnesiumsulfateoncorticosteroidresistantasthmaexacerbationarandomizedclinicaltrial AT qorbanimostafa effectsofnebulizedketamineandintravenousmagnesiumsulfateoncorticosteroidresistantasthmaexacerbationarandomizedclinicaltrial AT rezaeikojanimehdi effectsofnebulizedketamineandintravenousmagnesiumsulfateoncorticosteroidresistantasthmaexacerbationarandomizedclinicaltrial |